J&J's Stelara clinches ulcerative colitis nod to back up declining Remicade

21st October 2019 Uncategorised 0

Under assault from newer therapies in the anti-inflammatory market, Johnson & Johnson has focused on expanding Stelara beyond dermatology—and Monday, it took another big step in that direction. The FDA approved Stelara to treat adults with ulcerative colitis, a condition that affects around 910,000 U.S. patients per year.

More: J&J's Stelara clinches ulcerative colitis nod to back up declining Remicade
Source: fierce